Drug Database
HS

HSV-tk gene therapy (HSVtk / Zalmoxis / TK therapy)

✓ Approved

Megapharm Ltd · POLA1 · 细胞治疗

什么是 HSV-tk gene therapy?

HSV-tk gene therapy 是一种细胞治疗,由Megapharm Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名HSVtk, Zalmoxis, TK therapy
公司Megapharm Ltd
药物类别细胞治疗, 基因治疗
分子靶点POLA1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

HSV-tk gene therapy 作用于 1 个分子靶点:

POLA1DNA polymerase alpha 1, catalytic subunit (PDR, POLA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

HSV-tk gene therapy 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersChronic graft versus host disease✓ Approved

相关研究文献

PubMedOrphanet journal of rare diseases2026-11-19

AAV-mediated genetic interventions in the treatment of rare kidney disease: a narrative review.

Yafei Zhao Z, Qimin Zheng Z, Zhengying Fang F, Jingyuan Xie X

Chronic kidney disease (CKD) is one of the leading causes of global morbidity and mortality. As CKD progresses, it can lead to end-stage renal disease (ESRD), which requires treatment such as dialysis or kidney transplantation. Rare kidney diseases, a distinct subset of CKD, are primarily caused by genetic mutations. Due to the limited basic and clinical research on rare kidney diseases, treatment options remain limited, and the risk of progression to ESRD is higher compared to that of common CKD. As a result, there is an urgent need to explore novel therapeutic strategies. Gene therapy, which involves the use of genetic material to prevent or treat diseases, offers new hope for CKD and rare kidney diseases, including both monogenic and complex kidney disorders. The goal of gene therapy is to restore or degrade the defective proteins that cause the disease, necessitating editing of disease-causing genes and effective gene delivery. However, due to the unique physiological characteristics of the kidney, such as high blood flow in renal vessels, the lack of effective targeting mechanisms for specific renal cells, and the presence of the glomerular basement membrane barrier, developing effective gene therapy is rather challenge. The lack of a kidney specific vector poses an additional challenge. Recently, emerging studies have shown encouraging results using recombinant adeno-associated virus (rAAV) vectors in the treatment of renal diseases. Several rAAV-based gene therapy products have entered clinical use. In this review, we summarize the current advancements in gene therapy mediated by rAAV vectors for rare kidney disease, particularly monogenic kidney diseases that lead to CKD, and discuss the future directions in this field.Clinical trial number: Not applicable.

PMID 43053038
阅读全文 →
PubMedNanomedicine (London, England)2026-11-19

Applications of dendrimers for prostate cancer gene therapy: current status and future perspectives.

Kasurka Bilgesu B, Serry Moursy Enass E, Dufès Christine C

Prostate cancer remains a major global health burden, and metastatic castration-resistant prostate cancer remains incurable despite advances in systemic therapy. Gene and RNA therapeutics offer opportunities to target mechanisms that are difficult to modulate conventionally, but their translation is limited by delivery. Dendrimers are highly branched, generation-defined macromolecules that can condense and protect nucleic acids and be engineered with targeting ligands, steric stabilizers and stimuli-responsive components. This review critically evaluates dendrimer-based gene therapy for prostate cancer through an evidence-to-translation framework that separates direct therapeutic, platform and contextual evidence, while drawing selectively on the broader dendrimer literature to inform mechanism, design and translation. PAMAM and diaminobutyric poly(propylene imine) dendrimers dominate the field, with peptide dendrimers, dendrimersomes and hybrid nanomaterials expanding the design space. Reported therapeutic cargoes include siRNAs targeting Hsp27, BIRC5/survivin, cofilin-1 and MCL-1, plasmid-encoded MEG3, and cytokine-encoding plasmids. Although active targeting and systemic delivery have produced encouraging preclinical efficacy, major barriers remain, including serum instability, inefficient intracellular unpacking, limited biodistribution and pharmacokinetic data, cationic toxicity, and inadequate repeat-dose safety studies. Future progress will require biodegradable or ionizable architectures, clinically relevant metastatic models, biomarker-informed targeting, functional biodistribution, and scalable manufacturing.

PMID 43053339
阅读全文 →
PubMedOmics : a journal of integrative biology2026-11-19

Uncovering Critical Biomarkers, Immune Signatures, and Drug Candidates in Thyroid Cancer: A Systems Biology Approach.

Zohrabzadeh Maryam M, Vafadar Asma A, Dehghan Zeinab Z, Alibakhshi Abbas A et al.

Thyroid cancer (THCA) is the most common endocrine malignancy associated with clinical challenges like recurrence, aggressive variants, and therapy resistance. This study employed an integrative systems-biology approach to interrogate The Cancer Genome Atlas (TCGA)-THCA transcriptomic data to identify candidate genes and drug-target relationships for THCA. Differentially expressed genes (DEGs) were identified and used to construct protein-protein interaction and gene regulatory network (GRN) as well as generate topological, clustering, and enrichment analyses. Candidate genes were interrogated using survival analysis, genetic alteration, correlation, immune infiltration, drug-gene interaction, and molecular docking. Findings were independently validated in two Gene Expression Omnibus (GEO) cohorts. A total of 424 DEGs (191 up-regulated, 233 down-regulated) were identified. Seven candidate genes, DPP4, GABRB2, HMGA2, SERPINA1, ADH1B, KLHDC8A, and DLG2, were prioritized, and enrichment analyses revealed functional associations with extracellular matrix remodeling, MAPK signaling, cell-junction regulation, and synaptic signaling. These candidate genes displayed immune infiltration disparities and differential expression in independent GEO datasets. Docking simulations predicted favorable binding geometries for Sitagliptin-DPP4 and Flumazenil-GABRB2, while 100-ns molecular dynamics simulations further authenticated the binding affinities of these two complexes. In conclusion, we identified independent candidate genes and in-silico prioritized drug-target interactions for further preclinical investigations of THCA.

PMID 43052230
阅读全文 →
PubMedBMC ophthalmology2026-11-19

Traumatic cataract with secondary extreme axial elongation and posterior staphyloma: a case report.

Chen Yanchen Y, Li Shengnan S, Liu Qing Q, Liu Dongjing D et al.

Traumatic cataract complicated by secondary pathologic myopia and posterior staphyloma presents significant challenges to preoperative biometry accuracy and surgical strategy selection. Reports of complex cases involving long-standing trauma (> 30 years) with secondary extreme axial length (> 29 mm) and posterior staphyloma are rare, and systematic diagnostic and therapeutic experience remains limited. A 41-year-old male presented with a 30-year history of following a wooden stick injury. Left eye visual acuity was hand motion at 20 cm, with no improvement through either pinhole testing or refractive correction. His primary concerns included inability to perform fine visual tasks and progressive cosmetic deterioration due to esotropia. Notably, his elder sister had moderate myopia. Examination revealed characteristic "nine-petal" rosette-shaped lens opacification, an axial length of 29.99 mm, and secondary posterior staphyloma in the left eye. Diagnostic challenges included the inability to perform standard optical biometry due to the combination of dense lens opacity and posterior staphyloma, necessitating immersion B-mode ultrasound. Immersion B-mode ultrasound biometry was performed, and the Barrett TK Universal II formula was used to calculate intraocular lens (IOL) power with a target refraction of - 1.50 D. Uneventful phacoemulsification with capsular tension ring (CTR) implantation and IOL (+ 6.0 D) placement was performed. At 6-month follow-up, corrected distance visual acuity improved to 1.0 with a stable manifest refraction of - 1.75/-1.00 × 15°. No serious adverse events occurred; an unanticipated finding was a slight increase in esotropia with occasional diplopia, which did not compromise overall visual rehabilitation. Systematic evaluation (characteristic opacification identification, immersion ultrasound biometry, and assessment of secondary anatomic alterations) combined with individualized surgical strategy (CTR implantation and Barrett formula optimization) can achieve excellent visual outcomes even in the presence of secondary pathologic myopia and posterior staphyloma. This case provides clinical guidance for managing traumatic cataract with secondary anatomic alterations and highlights the critical value of precise biometry and capsular stability management in complex cases.

PMID 43052856
阅读全文 →
PubMedNature communications2026-11-19

Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer.

Wang Yan Y, Xu Hangcheng H, Zhou Yiran Y, Cui Liang L et al.

Bireociclib plus fulvestrant improves outcomes in hormone receptor-positive, HER2-negative advanced breast cancer, but molecular determinants of benefit and resistance remain unclear. Here we report an exploratory longitudinal circulating tumor DNA (ctDNA) analysis of the randomized phase Ⅲ BRIGHT-2 trial (ClinicalTrials.gov, NCT05077449) in female patients, profiling 596 plasma samples collected at baseline, on treatment, and at end of treatment with a 1,021-gene panel. Detectable baseline ctDNA and higher molecular tumor burden are associated with shorter progression-free survival in both arms, consistent with greater disease burden and intrinsic risk. MYC, PI3K-AKT and gBRCA/HRR alterations define adverse genomic risk, whereas PIK3CA-ESR1 status shows an exploratory treatment-informative signal. Landmark analyses link on-treatment ctDNA clearance or molecular tumor burden reduction with favorable subsequent outcomes. End-of-treatment profiling identifies candidate resistance-associated alterations after bireociclib, including FGFR1, MDM2, and MYC amplifications and MAPK pathway activation. Longitudinal ctDNA profiling may refine risk stratification, response monitoring, and resistance tracking during CDK4/6 inhibitor-based therapy.

PMID 43052301
阅读全文 →
PubMedCell death & disease2026-11-19

Loss of SNORD104-guided rRNA methylation promotes early adaptation to crizotinib in lung adenocarcinoma.

Mourksi Nour-El-Houda NE, Isaac Caroline C, Ripoll Julie J, Radermecker Julie J et al.

The ribosome, long considered an invariant actor of gene expression, recently emerged as a contributor to translational control through chemical modifications of ribosomal RNAs (rRNAs). These modifications are guided by small nucleolar RNAs (snoRNAs), which direct modifying enzymes to specific rRNA positions. Here, we report that lung adenocarcinoma (LUAD) cells that are resistant to tyrosine kinase inhibitors (TKIs) reshape both their translational program and rRNA 2'O-ribose methylation (2'Ome) profiles. EML4-ALK-positive LUAD cells that are resistant to crizotinib (ALK inhibitor) exhibit reduced global protein synthesis and a change in selective translation of mRNAs, encoding proteins previously linked to resistance. These cells show concomitant reduction in SNORD104 and 2'Ome at its associated 28S_Cm1327 position. Functional studies reveal that SNORD104 depletion abolishes 2'Ome at 28S_Cm1327 without affecting basal translation or cell viability, but enhances both under crizotinib exposure. Moreover, SNORD104 knockdown attenuates caspase activation and PARP cleavage during treatment, supporting reduced cell death. Altogether, our findings support a role for snoRNA-guided rRNA modification as a novel non-genomic mechanism in early adaptive responses to crizotinib therapy in LUAD.

PMID 43052254
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多HSV-tk gene therapy